IPO - GT Biopharma, Inc.

Form Type: S-1/A

Filing Date: 2025-02-07

Corporate Action: Ipo

Type: New

Accession Number: 000149315225005314

Filing Summary: GT Biopharma, Inc., a clinical stage biopharmaceutical company, is amending its registration statement for an initial public offering (IPO) under the Securities Act of 1933. The amendment pertains to the offering of up to 3,361,344 shares of common stock along with common and pre-funded warrants. The common stock will be offered at an assumed public offering price of $2.38 per share, based on the last reported price as of January 23, 2025. The offering is characterized as 'reasonable best efforts,' with no minimum number of shares required for closing; funds will not be held in escrow, which creates a potential risk for investors if the offering does not raise adequate proceeds for intended projects. The company is targeting the development of immuno-oncology therapies leveraging its proprietary TriKE® technology platforms. GT Biopharma’s strategic goal is to capture a significant share in the immuno-oncology market by developing next-generation therapies that utilize camelid nanobodies, enhancing the efficacy of treatments for various hematological malignancies and solid tumors. The estimated total expenses of the offering, excluding placement agent fees, will be approximately $390,531. This amendment reflects updates necessary to proceed with the IPO and attract investor interest in their promising clinical pipeline, including product candidates like GTB-3650, which targets CD33 in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The anticipated closing of the offering is set to occur no later than February 28, 2025, subject to fulfilling customary closing conditions.

Document Link: View Document

Form Type: S-1/A

Filing Date: 2025-01-27

Corporate Action: Ipo

Type: New

Accession Number: 000149315225003718

Filing Summary: GT Biopharma, Inc. is filing Amendment No. 1 to Form S-1 registration statement under the Securities Act of 1933. This document outlines a public offering of up to 3,361,344 shares of common stock at an assumed public offering price of $2.38 per share. In addition to the common stock, the offering includes up to 3,361,344 common warrants, pre-funded warrants, and placement agent warrants. The document emphasizes that the offering will terminate no later than February 28, 2025, unless earlier terminated by the company. GT Biopharma is classified as a Smaller Reporting Company and an Emerging Growth Company. The summary details a history of the company, including its focus on developing immuno-oncology products based on proprietary methods designed to enhance the cancer-killing abilities of natural killer cells. The document also references their product pipeline, including the suspension of clinical development for GTB-3550 and the advancement of GTB-3650 following favorable preclinical results. Lastly, various risk factors associated with the investment and the lack of minimum requirements for closing the offering are discussed.

Document Link: View Document

Form Type: S-1

Filing Date: 2024-12-23

Corporate Action: Ipo

Type: New

Accession Number: 000149315224051873

Filing Summary: GT Biopharma, Inc., a clinical-stage biopharmaceutical company, filed a registration statement concerning an initial public offering (IPO) to raise funds for the development of its proprietary immuno-oncology products. The Company focuses on leveraging its Tri-specific Killer Engager (TriKE®) and Tetra-specific Killer Engager (Dual Targeting TriKE®) platforms to treat a range of cancers and autoimmune disorders. GT Biopharma aims to commercially develop its first candidates like GTB-3650, targeted at myeloid leukemias, in clinical trials anticipated to start in early 2025. The company has exclusive rights to its TriKE® platform and seeks to attract investment to scale up its research and development efforts, including preclinical and clinical studies for GTB-5550 aimed at solid tumors. The filing indicates plans for a public offering of common stock with possible accompanying warrants, underscoring the firm’s commitment to advancing its clinical pipeline while managing capital risks, as highlighted by the lack of a minimum requirement for proceeds, thereby signaling potential variable investor outcomes.

Document Link: View Document